CYTOKINETICS INC

CYTK

CYTOKINETICS INC

CYTK

Insider Sentiment (TTM):

Last Purchase:-Last Sale:2026-06-29Shares Purchased (TTM):0Shares Sold (TTM):569,962

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:124,750,695Shares Outstanding:123,273,000Institutional Ownership Pct.:101.20%

Earnings Market Reaction:

Filing Date:2026-08-06Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	255	130	123	225	75	74	95	47	190	120	113	100
Available For Sale Securities Debt Securities Curr…	910	689	760	737	783	865	981	965	867	499	502	440
Accounts Receivable Net Current	24	7	18	2	8	2	17	0	0	1	1	2
Inventory Net	0	0	-	-	-	-	-	-	-	-	-	-
Prepaid Expense And Other Assets Current	18	14	17	13	20	16	15	7	11	19	12	20
Assets Current	1,208	839	917	977	887	956	1,108	1,019	1,068	639	628	561
Available For Sale Securities Debt Securities Nonc…	538	255	335	289	178	151	145	269	305	15	41	15
Property Plant And Equipment Net	79	82	79	76	70	67	66	64	66	68	69	76
Operating Lease Right Of Use Asset	73	75	76	78	76	77	75	76	77	78	79	80
Inventory Noncurrent	7	4	-	-	-	-	-	-	-	-	-	-
Other Assets Noncurrent	19	18	17	17	15	13	8	8	8	8	8	8
Assets	1,925	1,273	1,425	1,437	1,226	1,264	1,402	1,436	1,524	808	824	741
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	21	25	22	22	16	14	20	12	9	13	22	14
Accrued Liabilities Current	77	69	83	62	52	43	55	50	40	40	43	33
Operating Lease Liability Current	21	21	19	21	20	20	19	19	19	18	18	17
Long Term Debt Current	27	45	41	17	14	13	12	12	12	12	10	-
Derivative Liabilities Current	31	30	31	17	18	12	11	13	13	-	0	-
Deferred Revenue Current	2	2	2	2	1	52	52	-	-	-	0	-
Other Liabilities Current	3	9	4	2	10	6	10	6	10	6	11	14
Liabilities Current	181	199	202	142	131	160	180	110	103	89	103	78
Long Term Debt Noncurrent	248	247	246	159	159	92	93	93	93	57	58	61
Operating Lease Liability Noncurrent	102	105	108	111	111	113	113	115	117	119	120	122
Other Liabilities Noncurrent	-	-	-	2	2	3	0	0	0	0	0	0
Liabilities	2,098	2,100	2,084	1,958	1,594	1,530	1,537	1,450	1,415	1,204	1,211	1,179
Stockholders Equity
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital Common Stock	3,722	2,868	2,826	2,782	2,629	2,595	2,564	2,532	2,501	1,852	1,726	1,537
Accumulated Other Comprehensive Income Loss Net Of…	-4	-2	1	0	-0	2	2	5	-1	-1	-0	-1
Retained Earnings Accumulated Deficit	-3,892	-3,693	-3,487	-3,304	-2,998	-2,863	-2,702	-2,552	-2,391	-2,248	-2,112	-1,975
Stockholders Equity	-173	-827	-660	-521	-369	-266	-135	-14	109	-396	-386	-439
Liabilities And Stockholders Equity	1,925	1,273	1,425	1,437	1,226	1,264	1,402	1,436	1,524	808	824	741
Preferred Stock Par Or Stated Value Per Share	-	-	0.001	-	-	-	0.001	-	-	-	0.001	0.001
Preferred Stock Shares Authorized	-	-	10	-	-	-	10	-	-	-	10	-
Preferred Stock Shares Issued	-	-	0	-	-	-	0	-	-	-	0	-
Preferred Stock Shares Outstanding	-	-	0	-	-	-	0	-	-	-	0	-
Common Stock Par Or Stated Value Per Share	-	-	0.001	-	-	-	0.001	-	-	-	0.001	0.001
Common Stock Shares Authorized	-	-	326	-	-	-	326	-	-	-	163	-
Common Stock Shares Issued	-	-	123	-	-	-	118	-	-	-	102	-
Shares Outstanding	-	-	123	-	-	-	118	-	-	-	102	-

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-0.43%	6.62%	4.73%	-	-	-	-	-	-	-	-	-
2025	-8.68%	-2.38%	9.45%	0.23%	42.98%	64.06%	15.10%	6.62%	7.13%	-1.48%	6.51%	21.11%
2024	-21.88%	-12.75%	-3.88%	2.31%	-6.18%	-8.01%	-7.13%	-15.19%	-9.12%	-4.26%	-16.80%	-34.67%
2023	-	-	-	-	-	-	-11.98%	22.80%	122.91%	-7.76%	-7.58%	-18.55%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	6.66	4.21	4.53	6.88	6.76	5.99	6.17	9.28	10.39	7.19	6.12	7.22
Quick Ratio	6.56	4.14	4.45	6.78	6.61	5.89	6.08	9.22	10.28	6.98	6.00	6.97
Working Capital	1.03B	640.28M	714.52M	835.21M	755.48M	796.33M	928.27M	908.79M	965.03M	549.85M	525.37M	483.69M
Leverage & Debt
Debt to Equity	-12.09	-2.54	-3.16	-3.76	-4.32	-5.74	-11.35	-104.23	13.04	-3.04	-3.13	-2.69
Interest Coverage TTM	-20.52	-14.05	-13.43	-18.26	-18.89	-18.49	-14.22	-14.60	-14.83	-17.50	-17.53	-17.58
Debt Ratio	1.09	1.65	1.46	1.36	1.30	1.21	1.10	1.01	0.93	1.49	1.47	1.59
Efficiency & Turnover
Asset Turnover TTM	0.04	0.08	0.06	0.06	0.06	0.02	0.02	0.00	0.00	0.00	0.01	0.01
Days Sales Outstanding TTM	88.57	15.24	71.34	4.29	35.80	27.03	177.16	155.51	-	89.50	34.66	111.93
Receivables Turnover TTM	4.12	23.94	5.12	85.00	10.19	13.51	2.06	2.35	-	4.08	10.53	3.26
Per Share Metrics
Diluted EPS TTM	-6.77	-6.73	-6.54	-6.27	-5.08	-5.19	-5.26	-4.90	-4.99	-5.21	-5.45	-5.48
Free Cash Flow Per Share TTM	-4.40	-4.45	-4.45	-3.78	-3.67	-3.44	-3.57	-3.46	-3.67	-4.15	-4.31	-4.61
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	-	142.92%	-	-	-	-	304.08%	1,216.09%	1,189.18%	858.21%	475.91%	460.83%
Operating Profit Margin TTM	-1,046.12%	-605.06%	-695.44%	-656.95%	-637.96%	-2,943.30%	-2,902.72%	-16,297.79%	-16,148.37%	-13,272.04%	-6,589.71%	-6,344.43%
Net Profit Margin TTM	-1,321.12%	-784.02%	-891.60%	-862.21%	-707.17%	-3,201.47%	-3,191.11%	-17,906.24%	-17,398.82%	-14,141.74%	-6,988.63%	-6,739.96%
Growth Metrics
Net Revenue Growth (1Y)	-21.07%	450.60%	376.56%	2,609.26%	2,635.74%	412.21%	145.34%	-58.81%	-68.51%	-96.17%	-92.04%	-94.73%
Net Income Growth (1Y)	47.45%	34.84%	33.15%	30.45%	11.19%	15.96%	12.03%	9.43%	1.05%	23.17%	35.30%	86.69%
EPS Growth (1Y)	33.35%	29.61%	24.14%	27.96%	1.68%	-0.26%	-3.44%	-10.67%	-11.42%	15.00%	25.91%	82.19%
Valuation Metrics
P/E TTM	-12.59	-9.79	-9.72	-8.77	-6.51	-7.74	-8.94	-10.78	-10.85	-13.47	-15.31	-5.37
P/B TTM	-64.86	-9.83	-11.57	-12.65	-10.70	-17.88	-38.91	-446.68	54.52	-18.04	-20.86	-6.45
P/S TTM	166.28	76.78	86.68	75.61	46.03	247.81	285.13	1,930.34	1,888.52	1,904.56	1,070.22	362.16
Market Cap	11.25B	8.12B	7.63B	6.59B	3.95B	4.76B	5.27B	6.21B	5.92B	7.15B	8.06B	2.83B
Enterprise Value	11.27B	8.29B	7.80B	6.54B	4.05B	4.79B	5.28B	6.27B	5.83B	7.09B	8.01B	2.79B
Calculated Values
Free Cash Flow TTM	-580.72M	-548.92M	-534.82M	-453.38M	-438.72M	-407.57M	-399.80M	-407.05M	-401.27M	-422.57M	-415.75M	-443.03M
Net Debt	20.29M	162.17M	165.05M	-49.44M	98.52M	31.31M	9.89M	57.65M	-85.79M	-51.63M	-44.56M	-38.81M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Insider Transactions

2026-06-29Sale

Owner: Lee, Sung

Title: EVP, Chief Financial Officer

Shares: 3,134

Price/Share: $85.00

Value: $266,390.00

Shares Owned: 63,221

Relationship: Officer

Ownership: Direct

2026-06-24Sale

Owner: Lee, Sung

Title: EVP, Chief Financial Officer

Shares: 38,730

Price/Share: $82.30

Value: $3,187,479.00

Shares Owned: 63,221

Relationship: Officer

Ownership: Direct

2026-06-23Sale

Owner: Malik, Fady Ibraham

Title: EVP Research & Development

Shares: 3,500

Price/Share: $79.51

Value: $278,285.00

Shares Owned: 153,902

Relationship: Officer

Ownership: Direct

2026-06-15Sale

Owner: Blum, Robert I

Title: President & CEO

Shares: 7,500

Price/Share: $70.46

Value: $528,450.00

Shares Owned: 385,330

Relationship: Director,Officer

Ownership: Direct

2026-06-09Sale

Owner: Malik, Fady Ibraham

Title: EVP Research & Development

Shares: 3,500

Price/Share: $67.98

Value: $237,930.00

Shares Owned: 153,902

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-29	Lee, Sung	Officer	EVP, Chief Financial Officer	Direct	Sale	3,134	85.00	$266,390.00	63,221	4
2026-06-24	Lee, Sung	Officer	EVP, Chief Financial Officer	Direct	Sale	38,730	82.30	$3,187,479.00	63,221	4
2026-06-23	Malik, Fady Ibraham	Officer	EVP Research & Development	Direct	Sale	3,500	79.51	$278,285.00	153,902	4
2026-06-15	Blum, Robert I	Director,Officer	President & CEO	Direct	Sale	7,500	70.46	$528,450.00	385,330	4
2026-06-09	Malik, Fady Ibraham	Officer	EVP Research & Development	Direct	Sale	3,500	67.98	$237,930.00	153,902	4
2026-06-01	Callos, Andrew	Officer	EVP, Chief Commercial Officer	Direct	Sale	15,000	74.08	$1,111,200.00	58,555	4
2026-06-01	Parshall, B Lynne	Director	-	Direct	Sale	5,000	74.08	$370,400.00	15,784	4
2026-06-01	Kaye, Edward M. Md	Director	-	Direct	Sale	2,933	76.09	$223,171.97	10,283	4
2026-05-27	Blum, Robert I	Director,Officer	President & CEO	Direct	Sale	7,500	77.21	$579,075.00	392,830	4
2026-05-19	Malik, Fady Ibraham	Officer	EVP Research & Development	Direct	Sale	3,500	75.69	$264,915.00	153,902	4
2026-05-14	Blum, Robert I	Director,Officer	President & CEO	Direct	Sale	7,500	77.92	$584,400.00	400,330	4
2026-05-05	Lee, Sung	Officer	EVP, Chief Financial Officer	Direct	Sale	23,906	76.87	$1,837,654.22	63,221	4
2026-05-05	Callos, Andrew	Officer	EVP, Chief Commercial Officer	Direct	Sale	11,333	77.25	$875,474.25	58,555	4
2026-05-05	Malik, Fady Ibraham	Officer	EVP Research & Development	Direct	Sale	3,500	77.37	$270,795.00	153,902	4
2026-05-05	Wierenga, Wendell	Director	-	Direct	Sale	4,032	75.00	$302,400.00	32,637	4
2026-05-05	Henderson, John T	Director	-	Direct	Sale	20,000	75.97	$1,519,400.00	75,237	4
2026-05-01	Callos, Andrew	Officer	EVP, Chief Commercial Officer	Direct	Sale	15,857	65.00	$1,030,705.00	58,555	4
2026-04-30	Callos, Andrew	Officer	EVP, Chief Commercial Officer	Direct	Sale	15,000	63.26	$948,900.00	58,555	4
2026-04-29	Blum, Robert I	Director,Officer	President & CEO	Direct	Sale	7,500	59.62	$447,150.00	407,830	4
2026-04-21	Malik, Fady Ibraham	Officer	EVP Research & Development	Direct	Sale	3,500	65.69	$229,915.00	153,902	4
2026-04-15	Blum, Robert I	Director,Officer	President & CEO	Direct	Sale	7,500	65.38	$490,350.00	415,330	4
2026-04-15	Callos, Andrew	Officer	EVP, Chief Commercial Officer	Direct	Sale	7,449	66.02	$491,782.98	58,555	4
2026-04-07	Malik, Fady Ibraham	Officer	EVP Research & Development	Direct	Sale	4,500	64.98	$292,410.00	153,902	4
2026-04-01	Blum, Robert I	Director,Officer	President & CEO	Direct	Sale	7,500	66.63	$499,725.00	422,830	4
2026-03-31	Callos, Andrew	Officer	EVP, Chief Commercial Officer	Direct	Sale	3,639	65.00	$236,535.00	66,004	4
2026-03-18	Callos, Andrew	Officer	EVP, Chief Commercial Officer	Direct	Sale	1,930	62.07	$119,795.10	78,185	4
2026-03-17	Callos, Andrew	Officer	EVP, Chief Commercial Officer	Direct	Sale	8,542	62.15	$530,885.30	71,573	4
2026-03-17	Lee, Sung	Officer	EVP, Chief Financial Officer	Direct	Sale	4,935	62.15	$306,710.25	87,127	4
2026-03-17	Malik, Fady Ibraham	Officer	EVP Research & Development	Direct	Sale	12,033	62.15	$747,850.95	153,902	4
2026-03-17	Blum, Robert I	Director,Officer	President & CEO	Direct	Sale	36,601	62.15	$2,274,752.15	430,330	4
2026-03-16	Callos, Andrew	Officer	EVP, Chief Commercial Officer	Direct	Sale	1,709	61.03	$104,300.27	46,149	4
2026-03-09	Callos, Andrew	Officer	EVP, Chief Commercial Officer	Direct	Sale	2,582	60.72	$156,779.04	47,858	4
2026-03-09	Blum, Robert I	Director,Officer	President & CEO	Direct	Sale	7,931	60.72	$481,570.32	391,673	4
2026-03-09	Malik, Fady Ibraham	Officer	EVP Research & Development	Direct	Sale	2,907	60.72	$176,513.04	138,629	4
2026-03-05	Callos, Andrew	Officer	EVP, Chief Commercial Officer	Direct	Sale	26,000	61.88	$1,608,880.00	50,440	4
2026-03-02	Callos, Andrew	Officer	EVP, Chief Commercial Officer	Direct	Sale	886	61.62	$54,595.32	50,440	4
2026-03-02	Parshall, B Lynne	Director	-	Direct	Sale	5,000	61.21	$306,050.00	17,933	4
2026-02-05	Callos, Andrew	Officer	EVP, Chief Commercial Officer	Direct	Sale	15,000	61.93	$928,950.00	50,440	4
2026-02-02	Callos, Andrew	Officer	EVP, Chief Commercial Officer	Direct	Sale	886	62.10	$55,020.60	50,440	4
2026-01-05	Callos, Andrew	Officer	EVP, Chief Commercial Officer	Direct	Sale	15,000	60.28	$904,200.00	50,440	4
2026-01-02	Callos, Andrew	Officer	EVP, Chief Commercial Officer	Direct	Sale	1,798	62.62	$112,590.76	50,440	4
2025-12-29	Callos, Andrew	Officer	EVP, Chief Commercial Officer	Direct	Sale	1,809	62.44	$112,953.96	51,353	4
2025-12-22	Wierenga, Wendell	Director	-	Direct	Sale	20,000	66.14	$1,322,800.00	32,444	4
2025-12-16	Malik, Fady Ibraham	Officer	EVP Research & Development	Direct	Sale	2,200	61.24	$134,728.00	138,552	4
2025-12-08	Callos, Andrew	Officer	EVP, Chief Commercial Officer	Direct	Sale	1,042	65.96	$68,730.32	50,660	4
2025-12-05	Callos, Andrew	Officer	EVP, Chief Commercial Officer	Direct	Sale	52,486	65.95	$3,461,451.70	50,660	4
2025-12-02	Henderson, John T	Director	-	Direct	Sale	8,750	63.90	$559,125.00	74,578	4
2025-12-02	Malik, Fady Ibraham	Officer	EVP Research & Development	Direct	Sale	2,200	63.89	$140,558.00	140,610	4
2025-12-01	Kaye, Edward M. Md	Director	-	Direct	Sale	28,064	66.72	$1,872,430.08	9,977	4
2025-12-01	Harrington, Robert Arthur	Director	-	Direct	Sale	2,150	66.80	$143,620.00	18,542	4
2025-11-19	Parshall, B Lynne	Director	-	Direct	Sale	5,000	64.73	$323,650.00	22,933	4
2025-11-18	Malik, Fady Ibraham	Officer	EVP Research & Development	Direct	Sale	2,200	66.45	$146,190.00	140,610	4
2025-11-11	Kaye, Edward M. Md	Director	-	Direct	Sale	5,175	65.08	$336,789.00	9,977	4
2025-11-04	Malik, Fady Ibraham	Officer	EVP Research & Development	Direct	Sale	2,295	59.55	$136,667.25	140,610	4
2025-10-30	Blum, Robert I	Director,Officer	President & CEO	Direct	Sale	5,000	62.86	$314,300.00	358,108	4
2025-10-27	Wierenga, Wendell	Director	-	Direct	Sale	4,375	58.68	$256,725.00	32,444	4
2025-10-21	Malik, Fady Ibraham	Officer	EVP Research & Development	Direct	Sale	2,105	58.22	$122,553.10	140,610	4
2025-10-16	Blum, Robert I	Director,Officer	President & CEO	Direct	Sale	5,000	60.03	$300,150.00	363,108	4
2025-10-07	Malik, Fady Ibraham	Officer	EVP Research & Development	Direct	Sale	2,000	60.56	$121,120.00	140,610	4
2025-10-06	Kaye, Edward M. Md	Director	-	Direct	Sale	6,757	60.00	$405,420.00	9,778	4
2025-10-01	Blum, Robert I	Director,Officer	President & CEO	Direct	Sale	5,000	55.05	$275,250.00	368,108	4
2025-09-30	Kaye, Edward M. Md	Director	-	Direct	Sale	6,695	55.08	$368,760.60	16,535	4
2025-09-23	Malik, Fady Ibraham	Officer	EVP Research & Development	Direct	Sale	2,000	49.28	$98,560.00	140,610	4
2025-09-15	Blum, Robert I	Director,Officer	President & CEO	Direct	Sale	5,000	49.77	$248,850.00	373,108	4
2025-09-09	Malik, Fady Ibraham	Officer	EVP Research & Development	Direct	Sale	2,000	51.29	$102,580.00	140,610	4
2025-09-02	Kaye, Edward M. Md	Director	-	Direct	Sale	6,756	50.00	$337,800.00	23,230	4
2025-09-02	Blum, Robert I	Director,Officer	President & CEO	Direct	Sale	5,000	48.76	$243,800.00	378,108	4
2025-09-02	Harrington, Robert Arthur	Director	-	Direct	Sale	2,150	48.67	$104,640.50	20,493	4
2025-08-19	Malik, Fady Ibraham	Officer	EVP Research & Development	Direct	Sale	2,000	38.31	$76,620.00	140,610	4
2025-08-15	Blum, Robert I	Director,Officer	President & CEO	Direct	Sale	5,000	38.42	$192,100.00	383,108	4
2025-08-05	Malik, Fady Ibraham	Officer	EVP Research & Development	Direct	Sale	2,000	36.34	$72,680.00	140,610	4
2025-07-29	Blum, Robert I	Director,Officer	President & CEO	Direct	Sale	5,000	36.45	$182,250.00	388,108	4
2025-07-22	Malik, Fady Ibraham	Officer	EVP Research & Development	Direct	Sale	2,000	37.47	$74,940.00	140,610	4
2025-07-14	Blum, Robert I	Director,Officer	President & CEO	Direct	Sale	5,000	38.15	$190,750.00	393,108	4
2025-07-08	Malik, Fady Ibraham	Officer	EVP Research & Development	Direct	Sale	2,000	33.76	$67,520.00	140,610	4
2025-07-01	Blum, Robert I	Director,Officer	President & CEO	Direct	Sale	5,000	33.55	$167,750.00	398,108	4
2025-06-17	Malik, Fady Ibraham	Officer	EVP Research & Development	Direct	Sale	2,000	32.91	$65,820.00	140,610	4
2025-06-16	Blum, Robert I	Director,Officer	President & CEO	Direct	Sale	5,000	33.80	$169,000.00	403,108	4
2025-06-05	Kaye, Edward M. Md	Director	-	Direct	Sale	3,636	32.10	$116,715.60	29,658	4
2025-06-05	Callos, Andrew	Officer	EVP, Chief Commercial Officer	Direct	Sale	8,659	32.04	$277,434.36	52,028	4
2025-06-03	Malik, Fady Ibraham	Officer	EVP Research & Development	Direct	Sale	2,000	31.88	$63,760.00	140,610	4
2025-06-02	Blum, Robert I	Director,Officer	President & CEO	Direct	Sale	5,000	31.22	$156,100.00	408,108	4
2025-05-20	Malik, Fady Ibraham	Officer	EVP Research & Development	Direct	Sale	2,000	31.98	$63,960.00	140,255	4
2025-05-16	Blum, Robert I	Director,Officer	President & CEO	Direct	Sale	5,000	30.93	$154,650.00	412,629	4
2025-05-15	Bhanji, Muna	Director	-	Direct	Sale	1,454	29.73	$43,227.42	23,510	4
2025-05-06	Malik, Fady Ibraham	Officer	EVP Research & Development	Direct	Sale	2,000	35.01	$70,020.00	140,255	4
2025-05-05	Callos, Andrew	Officer	EVP, Chief Commercial Officer	Direct	Sale	4,002	36.68	$146,793.36	60,687	4
2025-04-29	Blum, Robert I	Director,Officer	President & CEO	Direct	Sale	5,000	40.96	$204,800.00	417,629	4
2025-04-22	Malik, Fady Ibraham	Officer	EVP Research & Development	Direct	Sale	2,000	38.11	$76,220.00	140,255	4
2025-04-21	Wierenga, Wendall	Director	-	Direct	Sale	20,000	38.46	$769,200.00	24,848	4
2025-04-15	Henderson, John T	Director	-	Direct	Sale	3,190	38.66	$123,325.40	66,348	4
2025-04-10	Blum, Robert I	Director,Officer	President & CEO	Direct	Sale	5,000	36.77	$183,850.00	422,629	4
2025-04-08	Malik, Fady Ibraham	Officer	EVP Research & Development	Direct	Sale	2,000	36.18	$72,360.00	140,255	4
2025-04-07	Callos, Andrew	Officer	EVP, Chief Commercial Officer	Direct	Sale	2,886	35.78	$103,261.08	64,689	4
2025-04-03	Harrington, Robert Arthur	Director	-	Direct	Sale	450	39.43	$17,743.50	14,658	4
2025-03-31	Blum, Robert I	Director,Officer	President & CEO	Direct	Sale	15,000	40.75	$611,250.00	427,629	4
2025-03-18	Malik, Fady Ibraham	Officer	EVP Research & Development	Direct	Sale	2,000	43.58	$87,160.00	140,455	4
2025-03-17	Malik, Fady Ibraham	Officer	EVP Research & Development	Direct	Sale	4,389	44.38	$194,783.82	101,005	4
2025-03-17	Blum, Robert I	Director,Officer	President & CEO	Direct	Sale	12,648	44.38	$561,318.24	326,533	4
2025-03-17	Callos, Andrew	Officer	EVP, Chief Commercial Officer	Direct	Sale	2,775	44.38	$123,154.50	34,888	4
2025-03-14	Callos, Andrew	Officer	EVP, Chief Commercial Officer	Direct	Sale	100	45.00	$4,500.00	37,663	4
2025-03-13	Callos, Andrew	Officer	EVP, Chief Commercial Officer	Direct	Sale	26,771	43.62	$1,167,751.02	37,663	4
2025-03-06	Blum, Robert I	Director,Officer	President & CEO	Direct	Sale	16,970	43.44	$737,176.80	364,181	4
2025-03-06	Callos, Andrew	Officer	EVP, Chief Commercial Officer	Direct	Sale	3,341	43.27	$144,565.07	64,434	4
2025-03-06	Malik, Fady Ibraham	Officer	EVP Research & Development	Direct	Sale	8,228	43.27	$356,025.56	105,394	4
2025-03-05	Blum, Robert I	Director,Officer	President & CEO	Direct	Sale	25,000	43.23	$1,080,750.00	381,151	4
2025-03-04	Harrington, Robert Arthur	Director	-	Direct	Sale	900	42.50	$38,250.00	15,108	4
2025-03-04	Malik, Fady Ibraham	Officer	EVP Research & Development	Direct	Sale	2,000	42.50	$85,000.00	116,071	4
2025-03-03	Callos, Andrew	Officer	EVP, Chief Commercial Officer	Direct	Sale	1,114	42.88	$47,768.32	67,775	4
2025-03-03	Malik, Fady Ibraham	Officer	EVP Research & Development	Direct	Sale	2,449	42.88	$105,013.12	113,622	4
2025-03-03	Blum, Robert I	Director,Officer	President & CEO	Direct	Sale	8,743	42.88	$374,899.84	406,151	4
2025-02-18	Malik, Fady Ibraham	Officer	EVP Research & Development	Direct	Sale	2,000	45.98	$91,960.00	116,071	4
2025-02-04	Malik, Fady Ibraham	Officer	EVP Research & Development	Direct	Sale	2,000	48.06	$96,120.00	116,071	4
2025-01-21	Malik, Fady Ibraham	Officer	EVP Research & Development	Direct	Sale	2,000	45.92	$91,840.00	116,071	4
2025-01-07	Malik, Fady Ibraham	Officer	EVP Research & Development	Direct	Sale	2,000	49.32	$98,640.00	116,071	4
2024-12-16	Wierenga, Wendall	Director	-	Direct	Sale	742	48.61	$36,068.62	24,559	4
2024-12-11	Henderson, John T	Director	-	Direct	Sale	1,780	50.42	$89,747.60	38,461	4
2024-12-10	Malik, Fady Ibraham	Officer	EVP Research & Development	Direct	Sale	7,300	50.64	$369,672.00	116,071	4
2024-12-02	Blum, Robert I	Director,Officer	President & CEO	Direct	Sale	5,000	50.76	$253,800.00	397,678	4
2024-11-26	Malik, Fady Ibraham	Officer	EVP Research & Development	Direct	Sale	7,300	50.16	$366,168.00	111,878	4
2024-11-25	Wierenga, Wendall	Director	-	Direct	Sale	742	50.00	$37,100.00	24,559	4
2024-11-18	Blum, Robert I	Director,Officer	President & CEO	Direct	Sale	5,000	50.55	$252,750.00	397,456	4
2024-11-12	Malik, Fady Ibraham	Officer	EVP Research & Development	Direct	Sale	6,342	58.48	$370,880.16	113,878	4
2024-11-01	Blum, Robert I	Director,Officer	President & CEO	Direct	Sale	5,000	51.63	$258,150.00	397,456	4
2024-10-30	Malik, Fady Ibraham	Officer	EVP Research & Development	Direct	Sale	7,300	51.92	$379,016.00	114,920	4
2024-10-28	Wierenga, Wendall	Director	-	Direct	Sale	4,452	52.25	$232,617.00	24,559	4
2024-10-15	Malik, Fady Ibraham	Officer	EVP Research & Development	Direct	Sale	7,300	54.19	$395,587.00	116,920	4
2024-10-09	Blum, Robert I	Director,Officer	President & CEO	Direct	Sale	5,000	55.61	$278,050.00	397,456	4
2024-10-01	Malik, Fady Ibraham	Officer	EVP Research & Development	Direct	Sale	7,300	52.10	$380,330.00	118,920	4
2024-09-30	Blum, Robert I	Director,Officer	President & CEO	Direct	Sale	5,000	52.14	$260,700.00	397,456	4
2024-09-17	Malik, Fady Ibraham	Officer	EVP Research & Development	Direct	Sale	7,300	56.76	$414,348.00	120,920	4
2024-09-16	Blum, Robert I	Director,Officer	President & CEO	Direct	Sale	5,000	55.99	$279,950.00	397,456	4
2024-09-09	Parshall, B Lynne	Director	-	Direct	Sale	5,000	54.92	$274,600.00	20,600	4
2024-09-03	Blum, Robert I	Director,Officer	President & CEO	Direct	Sale	5,000	57.03	$285,150.00	397,456	4
2024-09-03	Malik, Fady Ibraham	Officer	EVP Research & Development	Direct	Sale	7,384	57.00	$420,888.00	122,920	4
2024-08-26	Parshall, B Lynne	Director	-	Direct	Sale	5,000	57.26	$286,300.00	20,600	4
2024-08-20	Malik, Fady Ibraham	Officer	EVP Research & Development	Direct	Sale	7,300	56.24	$410,552.00	125,004	4
2024-08-12	Parshall, B Lynne	Director	-	Direct	Sale	5,000	55.20	$276,000.00	20,600	4
2024-08-12	Blum, Robert I	Director,Officer	President & CEO	Direct	Sale	11,500	55.17	$634,455.00	399,412	4
2024-08-06	Malik, Fady Ibraham	Officer	EVP Research & Development	Direct	Sale	7,300	53.72	$392,156.00	121,704	4
2024-07-30	Blum, Robert I	Director,Officer	President & CEO	Direct	Sale	11,500	59.49	$684,135.00	399,412	4
2024-07-29	Parshall, B Lynne	Director	-	Direct	Sale	5,000	59.84	$299,200.00	20,600	4
2024-07-23	Malik, Fady Ibraham	Officer	EVP Research & Development	Direct	Sale	7,300	57.02	$416,246.00	129,004	4
2024-07-15	Parshall, B Lynne	Director	-	Direct	Sale	5,000	55.82	$279,100.00	20,600	4
2024-07-10	Blum, Robert I	Director,Officer	President & CEO	Direct	Sale	11,500	54.29	$624,335.00	399,412	4
2024-07-09	Malik, Fady Ibraham	Officer	EVP Research & Development	Direct	Sale	7,300	55.90	$408,070.00	131,004	4
2024-07-05	Harrington, Robert Arthur	Director	-	Direct	Sale	253	54.61	$13,816.33	15,516	4
2024-07-01	Blum, Robert I	Director,Officer	President & CEO	Direct	Sale	11,500	54.05	$621,575.00	405,145	4
2024-07-01	Parshall, B Lynne	Director	-	Direct	Sale	5,000	54.22	$271,100.00	20,600	4
2024-06-25	Malik, Fady Ibraham	Officer	EVP Research & Development	Direct	Sale	7,300	53.72	$392,156.00	133,004	4
2024-06-17	Parshall, B Lynne	Director	-	Direct	Sale	5,000	52.55	$262,750.00	20,600	4
2024-06-17	Blum, Robert I	Director,Officer	President & CEO	Direct	Sale	22,500	52.60	$1,183,500.00	416,645	4
2024-06-11	Malik, Fady Ibraham	Officer	EVP Research & Development	Direct	Sale	7,788	53.04	$413,075.52	135,004	4
2024-06-10	Bhanji, Muna	Director	-	Direct	Sale	2,000	52.07	$104,140.00	17,631	4
2024-06-04	Blum, Robert I	Director,Officer	President & CEO	Direct	Sale	22,500	48.85	$1,099,125.00	439,145	4
2024-06-03	Parshall, B Lynne	Director	-	Direct	Sale	5,000	48.64	$243,200.00	15,600	4
2024-06-03	Wong, Robert	Officer	VP, Chief Accounting Officer	Direct	Sale	13,011	48.88	$635,977.68	16,653	4
2024-06-03	Harrington, Robert Arthur	Director	-	Direct	Sale	1,580	48.64	$76,851.20	15,541	4
2024-05-07	Malik, Fady Ibraham	Officer	EVP Research & Development	Direct	Sale	15,547	65.11	$1,012,265.17	137,056	4
2024-04-25	Henderson, John T	Director	-	Direct	Sale	10,562	64.54	$681,671.48	32,070	4
2024-04-09	Malik, Fady Ibraham	Officer	EVP Research & Development	Direct	Sale	32,605	74.32	$2,423,203.60	138,567	4
2024-03-05	Malik, Fady Ibraham	Officer	EVP Research & Development	Direct	Sale	32,604	67.54	$2,202,074.16	138,973	4
2024-02-14	Henderson, John T	Director	-	Direct	Sale	5,000	76.48	$382,400.00	42,632	4
2024-02-13	Blum, Robert I	Director,Officer	President & CEO	Direct	Sale	12,500	76.85	$960,625.00	441,797	4
2024-02-06	Malik, Fady Ibraham	Officer	EVP Research & Development	Direct	Sale	32,605	79.29	$2,585,250.45	142,973	4
2024-01-31	Blum, Robert I	Director,Officer	President & CEO	Direct	Sale	12,500	79.57	$994,625.00	441,797	4
2024-01-19	Blum, Robert I	Director,Officer	President & CEO	Direct	Sale	12,500	81.42	$1,017,750.00	441,797	4
2024-01-12	Henderson, John T	Director	-	Direct	Sale	5,000	85.14	$425,700.00	42,632	4
2024-01-04	Malik, Fady Ibraham	Officer	EVP Research & Development	Direct	Sale	15,678	86.98	$1,363,672.44	146,973	4
2024-01-02	Blum, Robert I	Director,Officer	President & CEO	Direct	Sale	12,500	85.08	$1,063,500.00	441,797	4
2023-12-27	Wierenga, Wendall	Director	-	Direct	Sale	10,000	73.60	$736,000.00	18,653	4
2023-12-18	Blum, Robert I	Director,Officer	President & CEO	Direct	Sale	12,500	36.95	$461,875.00	441,797	4
2023-12-18	Henderson, John T	Director	-	Direct	Sale	2,458	36.34	$89,323.72	42,380	4
2023-11-30	Blum, Robert I	Director,Officer	President & CEO	Direct	Sale	12,500	32.99	$412,375.00	441,417	4
2023-11-15	Blum, Robert I	Director,Officer	President & CEO	Direct	Sale	12,500	34.57	$432,125.00	441,417	4
2023-11-09	Malik, Fady Ibraham	Officer	EVP Research & Development	Direct	Sale	2,500	35.40	$88,500.00	150,664	4
2023-10-30	Blum, Robert I	Director,Officer	President & CEO	Direct	Sale	12,500	32.17	$402,125.00	441,417	4
2023-10-16	Blum, Robert I	Director,Officer	President & CEO	Direct	Sale	12,500	33.70	$421,250.00	441,417	4
2023-10-12	Malik, Fady Ibraham	Officer	EVP Research & Development	Direct	Sale	2,500	35.89	$89,725.00	153,164	4
2023-10-06	Blum, Robert I	Director,Officer	President & CEO	Direct	Sale	12,500	30.00	$375,000.00	441,417	4
2023-09-14	Malik, Fady Ibraham	Officer	EVP Research & Development	Direct	Sale	2,500	34.86	$87,150.00	155,664	4
2023-09-13	Blum, Robert I	Director,Officer	President & CEO	Direct	Sale	12,500	34.90	$436,250.00	441,417	4
2023-08-25	Blum, Robert I	Director,Officer	President & CEO	Direct	Sale	12,500	33.99	$424,875.00	441,417	4
2023-08-21	Wierenga, Wendall	Director	-	Direct	Sale	6,020	32.02	$192,760.40	18,205	4
2023-08-11	Blum, Robert I	Director,Officer	President & CEO	Direct	Sale	12,500	32.37	$404,625.00	441,417	4
2023-08-10	Malik, Fady Ibraham	Officer	EVP Research & Development	Direct	Sale	2,500	31.70	$79,250.00	158,164	4
2023-08-01	Blum, Robert I	Director,Officer	President & CEO	Direct	Sale	12,500	32.63	$407,875.00	441,417	4
2023-07-13	Blum, Robert I	Director,Officer	President & CEO	Direct	Sale	12,500	35.28	$441,000.00	441,417	4
2023-07-13	Malik, Fady Ibraham	Officer	EVP Research & Development	Direct	Sale	2,500	35.37	$88,425.00	160,664	4
2023-07-07	Bhanji, Muna	Director	-	Direct	Sale	2,000	34.12	$68,240.00	14,031	4
2023-07-03	Blum, Robert I	Director,Officer	President & CEO	Direct	Sale	12,500	32.60	$407,500.00	441,417	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Institutional Ownership

No data available for chart

2026-03-31

101.20%

Inst. Shares: 124,750,695

Shares Outstanding: 123,273,000

2025-12-31

97.66%

Inst. Shares: 117,295,726

Shares Outstanding: 120,103,000

2025-09-30

98.07%

Inst. Shares: 117,665,234

Shares Outstanding: 119,982,000

2025-06-30

97.63%

Inst. Shares: 116,628,414

Shares Outstanding: 119,457,000

2025-03-31

102.51%

Inst. Shares: 121,468,390

Shares Outstanding: 118,496,000

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	124,750,695	123,273,000	101.20%
2025-12-31	117,295,726	120,103,000	97.66%
2025-09-30	117,665,234	119,982,000	98.07%
2025-06-30	116,628,414	119,457,000	97.63%
2025-03-31	121,468,390	118,496,000	102.51%
2024-12-31	116,294,980	111,979,000	103.85%
2024-09-30	120,472,475	117,685,000	102.37%
2024-06-30	123,119,670	109,240,000	112.71%
2024-03-31	105,429,051	101,924,000	103.44%
2023-12-31	103,492,815	96,524,000	107.22%
2023-09-30	100,764,361	96,071,000	104.89%
2023-06-30	98,242,488	95,755,000	102.60%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

CYTOKINETICS INC (CYTK) — SEC Financial Statements & Analysis

CYTOKINETICS INC (CYTK) is a pharmaceutical preparations company. CYTOKINETICS INC trades on Nasdaq as: CYTK. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), CYTOKINETICS INC reported a -21.07% year-over-year revenue growth, a Gross Profit Margin of 142.92% (TTM), a Debt-to-Equity ratio of -12.09x, a Price-to-Sales (P/S) ratio of 166.28x (TTM), a Price-to-Book (P/B) ratio of -64.86x (TTM), at a market cap of $11.25B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -21.07%
Gross Profit Margin TTM: 142.92%
Debt To Equity: -12.09x
P/S TTM: 166.28x
P/B TTM: -64.86x
Market Cap: $11.25B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is CYTOKINETICS INC in?

CYTOKINETICS INC (CYTK) operates in the Pharmaceutical Preparations industry.

What is CYTK's market cap?

CYTOKINETICS INC (CYTK) has a market capitalization of $11.25B as of 2026-06-30.

What exchange does CYTK trade on?

CYTOKINETICS INC (CYTK) trades on the Nasdaq.